Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: December 2011

58 - Management of bladder and sexual dysfunction in multiple sclerosis

from Section IV - Therapy in clinical practice


Multiple sclerosis (MS) individuals who use complementary and alternative medicine (CAM) generally do so because they experience improvement in their quality of life, and in various MS symptoms such as fatigue, spasticity, or pain. The different CAM therapies used commonly by individuals with MS are: mind-body therapies, dietary changes and supplement use that include low fat diet, essential fatty acids and anti-oxidants, ginseng, acupuncture, low-dose naltrexone and cannabis. Despite the widespread use of CAM therapies among MS patients, most of these therapies have not been evaluated in well-designed, randomized, controlled clinical trials, the lack of which is the main reason why most neurologists do not incorporate CAM therapies into their management of MS patients. Clearly there are certain therapies, such as anti-oxidants and essential fatty acids, which have a scientific rationale for use in MS and are also supported by preclinical or pilot clinical data.

Related content

Powered by UNSILO


1. Nakipoglu GF, Kaya AZ, Orhan G, et al. Urinary dysfunction in multiple sclerosis. J Clin Neurosci 2009; 16:1321–4.
2. Goldstein I, Siroky MB, Sax DS, Krane RJ. Neurologic abnormalities in multiple sclerosis. J Urol 1982; 128:541–5.
3. Andersen JT, Bradley WE. Abnormalities of detrusor and sphincter function in multiple sclerosis. Br J Urol 1976; 43:193–8.
4. Bradley WE. Urinary bladder dysfunction in multiple sclerosis. Neurology 1978; 29:52–8.
5. Koldewijn EL, Hommes OR, Lemmens WA, et al. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995; 154:169–73.
6. Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999; 246:1027–32.
7. DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002; 15:271–8.
8. De Seze M., Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13:915–28.
9. Nortvedt MW, Riise T, Frugaard J, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007; 13:106–12.
10. Brazis PW, Masdeu JC, Biller J. Localization in Clinical Neurology. Philadelphia: Lippincott, Williams and Wilkins, 2007.
11. Hockel M. Basic neuroanatomy and neurophysiology of the urethrovesical function with special reference to extended hysterectomy. CME J Gynecologic Oncol 2002; 7:32–5.
12. Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 2003; 169:1384–7.
13. Fog T. Topographic distribution of plaques in the spinal cord in multiple sclerosis. Arch Neurol Psychol 1950; 63:382–414.
14. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978; 4:151–62.
15. Nathan PW, Smith MC. The centrifugal pathway for micturition within the spinal cord. J Neurol 1958; 21:177–89.
16. Blaivas JG, Barbalias GA. Detrusor external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol 1984; 131:91–4.
17. Blaivas JG. The neurophysiology of micturition: a clinical study of 550 patients. J Urol 1982; 127:958–63.
18. Blaivas JG, Bhimani G, Labib KB. Vesicourethral dysfunction in multiple sclerosis. J Urol 1979; 122:342–7.
19. Siroky MB, Krane RJ. Neurologic aspects of detrusor-sphincter dyssynergia, with reference to the guarding reflex. J Urol 1982; 127:953–7.
20. McGuire EJ, Savastano JA. Urodynamic findings and long term outcome management of patients with multiple sclerosis-induced lower urinary tract dysfunction. J Urol 1984; 132:713–15.
21. Betts CD, D’Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psych 1993; 56:245–50.
22. Mayo ME, Chetner MP. Lower urinary tract dysfunction in multiple sclerosis. Urology 1992; 39:67–70.
23. Awad SA, Gajewski JB, Sogbein SK, et al. Relationship between neurologic and urologic status in patients with multiple sclerosis. J Urol 1984; 139:499–502.
24. Philip T, Read DJ, Higson RH. The urodynamic characteristics of multiple sclerosis. Br J Urol 1981; 53:672–5.
25. Hinson JL, Boone TB. Urodynamics and multiple sclerosis. Urol Clin North Am 1996; 23:475–81.
26. Kruse MN, Mallory BS, Noto HL, et al. Modulation of the spinobulbospinal micturition reflex in cats. Am J Physiol 1992; 262:478–84.
27. Kruse MN, Mallory BS, Noto H. Properties of the descending limb of the spinal-bulbospinal reflex pathway in the cat. Brain Res 1991; 556:6–12.
28. Andersen JT, Bradley WF. Bladder and urethral innervation in multiple sclerosis. Br J Urol 1976; 48:239–43.
29. Eardley I, Nagendran K, Lecky B, et al. Neurophysiology of the striated sphincter muscle in multiple sclerosis. Br J Urol 1991; 68:81–8.
30. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006; 85:536–45.
31. Bemelmans BL, Hommes OR, Van Kerrebroeck PE, et al. Evidence for early lower urinary tract dysfunction in multiple sclerosis. J Urol 1991; 145:1219–24.
32. Francis GS, Evans AC, Arnold DL. Neuroimaging in multiple sclerosis. Neurol Clin 1995; 13:147–71.
33. Filippi M, Miller DH. Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis. Curr Opin Neurol 1996; 9:178–86.
34. Kim YH, Goodman C, Omessi E, et al. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 1998; 159:972–6.
35. Pozzilli C, Grasso MG, Bastianello S, et al. Structural correlates of neurourologic abnormalities in multiple sclerosis. Eur Neurol 1992; 32:228–30.
36. Stevens JC, Kinkel WR, Polachini I. Clinical correlation in 64 patients with multiple sclerosis. J Neurol 1986; 43:1145–8.
37. Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39:161–6.
38. Kragt JJ, Hoogervorst LJ, Uitdehaag MJ, Polman CH. Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis. Neurology 2004; 63:1716–18.
39. Sirls LT, Zimmern PE, Leach GE. Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. J Urol 1994; 151:946–50.
40. Van Poppel H, Baert L. Treatment of multi-resistant urinary infections in patients with multiple sclerosis. Pharmacol Weekly 1987; 9(Suppl):76–7.
41. Shumaker SA, Wyman JF, Uebersax JS, et al. Health related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogential Distress Inventory. Qual Life Res 1994; 3:291–306.
42. Raz S, Erickson DR. SEAPI QMM incontinence classification system. Neurourol Urodyn 1992; 11:187–99.
43. Bonniaud V, Bryant D, Parratte B, Guyatt G. Qualiveen, a urinary-disorder specific instrument: 0.5 corresponds to the minimal important difference. J Clin Epid 2008; 61:505–10.
44. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:470–7.
45. Fowler CJ. Bladder dysfunction in multiple sclerosis: causes and treatment. Int Mult Scler J 1996; 1:431–40.
46. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Med Microbiol 2004; 38:1150–7.
47. Jefferson H, Dalton HP, Escobar MR, Allison MJ. Transportation delay and the microbiological quality of clinical specimens. Am J Clin Pathol 1975; 64:689–93.
48. Reller ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Med Microbiol 2004; 38:1150–8.
49. Pappas PG. Laboratory in the diagnosis and management of urinary tract infections. Med Clin N Am 1991; 75:313–25.
50. Samellas W, Rubin B. Management of upper urinary tract complications of multiple sclerosis by means of urinary diversion to an ileal conduit. J Urol 1965; 93:169.
51. Franz DA, Towler MA, Edlich RF, Steers WD. Functional urinary outlet obstruction causing urosepsis in a male multiple sclerosis patient. J Emerg Med 1992; 10:281–4.
52. Onal B, Siva A, Buldu I, et al. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Int Braz J Urol 2009; 35:326–33.
53. Krhut J, Hradilek P, Zalpetalova O. Analysis of the upper urinary tract function in multiple sclerosis patients. Acta Neurol Scand 2008; 118:115–19.
54. Beck RP, Warren KG, Whitman P. Urodynamic studies in female patients with multiple sclerosis. Am J Obstet Gynecol 1981; 139:273–6.
55. Bradley WE, Logothetis JL, Timm GW. Cystometric and sphincter abnormalities in multiple sclerosis. Neurology 1973; 23:1131–9.
56. Gonor SE, Carroll DJ, Metcalfe JB. Vesical dysfunction in multiple sclerosis. Urology 1985; 128:541–5.
57. Peterson T, Pederson J. Neurourodynamic evaluation of voiding dysfunction in multiple sclerosis. Acta Neurol Scand 1984; 69:402–11.
58. Piazza DH, Diokno AC. Review of neurogenic bladder in multiple sclerosis. Urology 1979; 14:33–5.
59. Schoenberg HW, Gutrich K, Banno J. Urodynamic patterns in multiple sclerosis. J Urol 1979; 122:648–50.
60. Sirls LT, Weese D, Zimmern PE. Intravesical oxybutynin for refractory detrusor overactivity. Presented at the Annual Meeting of the Urodynamics Society, San Antonio, TX, 1993.
61. Summers JL. Neurogenic bladder in the women with multiple sclerosis. J Urol 1978; 120:555–6.
62. Weinstein MS, Cardenas DD, O’Shughnessy EJ, Catanzaro ML. Carbon dioxide cystometry and postural changes in patients with multiple sclerosis. Arch Phys Med Rehabil 1988; 69:923–7.
63. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 1999; 161:743–57.
64. Lemack GE, Frohman E, Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology 2007; 69:893–897.
65. Chancellor MB, Blaivas JG. Multiple sclerosis and diabetic neurogenic bladder. In Blaivas JG, Chancellor MB, eds. Atlas of Urodynamics, 1st edn. Philadelphia PA: Lippincott Williams & Wilkins, 1996, 187–9.
66. Bakke A, Myhr KM, Gronning M, Nyland H. Bladder, bowel and sexual dysfunction in patients with multiple sclerosis: a cohort study. Scand J Urol Nephrol 1996; 179(Suppl):61–6.
67. Webb RJ, Lawson AL, Neal DE. Clean intermittent self-catheterization in 172 adults. Br J Urol 1990; 65:20–3.
68. Hebjorn S. Treatment of detrusor hyperreflexia in multiple sclerosis: a double blind cross over clinical trial comparing methantheline bromide (Banthine), flavoxate chloride (Uripas) and meladrazine tartarate (Lisidonil). Urol Int 1977; 32:209–17.
69. Rabey JM, Moriel EZ, Farkas A, et al. Detrusor hyperreflexia in multiple sclerosis. Alleviation by combination of imipramine and propantheline, a clinico-laboratory study. Eur Neurol 1979; 18:33–7.
70. Schoenberg HW, Gutrich JM. Management of vesical dysfunction in multiple sclerosis: the role of drug therapy. Urology 1980; 16:444–7.
71. Awad SA, Wilson JW, Fenemore J, Kiruluta HG. Dysfunction of the detrusor and urethra in multiple sclerosis: the role of drug therapy. Can J Surg 1982; 25:259–62.
72. Blaivas JG, Kaplan SA. Urologic dysfunction in patients with multiple sclerosis. Semin Neurol 1988; 8:159–65.
73. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62:237–42.
74. Cardozo L, Lisec M, Millard R, et al. Randomized, double blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172:1919–24.
75. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95:993–1001.
76. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo controlled, randomized, double blind, multicenter clinical trial. BJU Int 2000; 85:659–64.
77. Blaivas JG, Sinha HP, Zayed AA, Labib KB. Detrusor-external sphincter dyssynergia. J Urol 1981; 125:542–4.
78. Dibenedetto M, Yalla SV. Electrodiagnosis of striated urethral sphincter dysfunction. J Urol 1978; 122:361–5.
79. Miklos JR, Sze EH, Karram MM. A critical approach of the methods of measuring leak point pressures in women with stress incontinence. Obstet Gynecol 1995; 86:349–52.
80. Miller H, Simpson CA, Yeates WK. Bladder dysfunction in multiple sclerosis. Br Med J 1965; 1:1265–9.
81. Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009, Issue 1. Art. No.: CD004193. DOI: 10.1002/14651858.CD004193.pub2
82. Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006; 195:1730–5.
83. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78:696–702.
84. Davila GW. Transdermal oxybutynin: a new treatment for overactive bladder. Expert Opin Pharmacol 2003; 4:2315–24.
85. Wein AJ. Pharmacologic approaches to the management of bladder dysfunction. J Contin Educ Urol 1979; 18:17.
86. Diokno AC, Lapides J. Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972; 108:307–9.
87. Nilvebrant L, Hallen B, Larsson G. Tolterodine – a new bladder selective muscarine receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60:1129–36.
88. Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor over activity and symptoms of frequency, urge incontinence and urgency: urodynamic evaluation. World J Urol 1997; 15:144–51.
89. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47:376–84.
90. Dmochowski RR, Rosenberg MT, Zinner NR, Staskin DR, Sand PK. Extended-release trospium chloride improves quality of life in overactive bladder. Value Health. 2010; 13(2):251–7.
91. Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001; 19:299–306.
92. Kavia RBC, de Ridder D, Constantinescu CS, Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010; 16:1349–59.
93. Tompson IM, Lauvetz R. Oxybutynin in bladder spasms, neurogenic bladder and enuresis. Urology 1976; 8:452–4.
94. Brooks ME, Braf ZF. Oxybutynin chloride (Ditropan) clinical uses and applications. Paraplegia 1980; 18:64–8.
95. Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980; 52:472–5.
96. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145:813–17.
97. Tapp AJ, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post menopausal women with oxybutynin hydrochloride, a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97:521–6.
98. Fowler CJ, Van Kerrebroeck PE, Nordenbo A, Van Poppel H. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. J Neurol 1992; 55:986–9.
99. Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 1991; 28:84–90.
100. Greenfield SP, Fera M. Intravesical oxybutynin in children with neurogenic bladder. J Urol 1991; 146:532–4.
101. Mohler JL. Relaxation of intestinal bladders by intravesical oxybutynin chloride. Neurourol Urodyn 1990; 9:179–82.
102. Brendler CB, Radelbaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989; 141:350–2.
103. Higson RH, Smith JC, Hills W. Intravesical lidocaine and detrusor instability. Br J Urol 1979; 51:500–3.
104. Mattiasson A, Ekstrom B, Anderson KE. Effects of instillation of verapamil into patients with detrusor hyperactivity. Neurourol Urodyn 1987; 6:253–6.
105. Wees DL, Rosenkamp DA, Zimmern PE. Intravesical oxybutynin: experience with 42 patients. Urology 1993; 41:527–30.
106. Sharkey KA, Williams RG, Schultzberg WM. Sensory substance P-innervation of the urinary bladder: possible site of action of capsaicin in causing urinary retention in rats. Neuroscience 1983; 10:861–8.
107. Szallasi A, Blumberg P. Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci 1990; 47:1339–408.
108. Maggi CA, Barbanti G, Santicioli P, et al. Cystometric evidence that capsaicin sensitive nerves modulate the afferent branch of the micturition reflex in humans. J Urol 1989; 142:150–4.
109. De Ridder D, Chandiramani V, Dasgupta P, et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long term follow-up. J Urol 1997; 158:2087–92.
110. Fowler CJ, Beck RO, Gerrard S, et al. Intravesical capsaicin for the treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57:169–73.
111. Fowler CJ, Jewkes D, McDonald WI, et al. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992; 339:1239.
112. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 1997; 158:2093–6.
113. Hilton P, Hertogs K, Stanton SL. The use of desmopressin for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983; 46:854–5.
114. Kinn AC, Larsson PO. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scand J Urol Nephrol 1990; 24:109–12.
115. Eckford SD, Carter PG, Jackson SR, et al. An open in-patient incremental safety study of desmopressin in women with multiple sclerosis and nocturia. Br J Urol 1995; 76:459–63.
116. Valiquette G, Herbert J, D’Alisera PM. Desmopressin in the management of nocturia in patients with multiple sclerosis. Arch Neurol 1996; 53:1270–5.
117. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174:196–200.
118. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 2005; 24:2–12.
119. Kabay S, Kabay SC, Yucel M, Ozden H, Yilmaz Z, Aras O, Aras B. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009; 28:964–8.
120. Nordling J. Alpha blockers and urethral pressure in neurological patients. Urol Int 1978; 33:304–9.
121. O’Roirdan JI, Doherty C, Javed M, et al. Do alpha blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995; 153:1114–16.
122. Kornhuber HH, Schutz A. Efficient treatment of neurogenic bladder disorders in multiple sclerosis with intermittent catheterization and ultrasound controlled training. Eur J Neurol 1990; 30:260–7.
123. Khan F, Pallant JF, Pallant JI, Brand C, Kilpatrick TJ. A randomized controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81:1033–8.
124. Hollander JB, Diokno AC. Urinary diversion and reconstruction in the patient with spinal cord injury Urol Clin North Am 1993; 20:465–74.
125. Van Balken MR, Vergunst H, Bemelmans BLH. The use of electrical devices for the treatment of bladder dysfunction: a review of methods. J Urol 2004; 172:846–51.
126. Schwartz SL, Kennelly MJ, McGuire EJ, Faerber GJ. Incontinent ileo-vesicostomy urinary diversion in the treatment of lower urinary tract dysfunction. J Urol 1994; 152:99–102.
127. Juma S, Niku SD, Brodak PP, Joseph AC. Urolume urethral wall stent in the treatment of detrusor sphincter dyssynergia. Paraplegia 1994; 32:616–21.
128. Sauerwein D, Gross AJ, Kutzenberger J, Ringert RH. Wallstents in patients with detrusor sphincter dyssynergia. J Urol 1995; 154:495–7.
129. Maruf NJ, Godec CJ, Strom RL, Cass AS. Unusual therapeutic response of massive squamous cell carcinoma of the bladder. J Urol 1982; 128:1313–15.
130. Broecher BH, Klein FA, Hackler RH. Cancer of the bladder in spinal cord injury patients. J Urol 1981; 125:196–7.
131. Bejany EC, Lockhart JL, Rhamy RK. Malignant vesical tumors following spinal cord injury. J Urol 1987; 138:1390–2.
132. Sutton MA, Hinson JL, Nickell KG, Boone TB. Continent ileocecal augmentation cystoplasty. Spinal Cord 1998; 36:246–51.
133. Appell RA. Electrical stimulation for the treatment of urinary incontinence. Urology 1998; 51(Suppl 2A):24–6.
134. Siegel SW, Catanzaro F, Dijkema HE, et al. Longterm results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000; 56(Suppl 1):87–91.
135. Haab F, Zimmern PE, Leach GE. Female stress incontinence due to intrinsic sphincter deficiency: recognition and management. J Urol 1996; 165:3–17.
136. Winters JC, Appell R. Periurethral injection of collagen in the treatment of intrinsic sphincteric deficiency in the female patient. Urol Clin North Am 1995; 22:673–8.
137. Light JK, Pietro T. Alteration in detrusor behavior and the effect on renal function following insertion of the artificial urinary sphincter. J Urol 1986; 136:632–5.
138. Lilius HG, Valtonen EJ, Wikstrom J. Sexual problems in patients suffering from multiple sclerosis. J Chron Dis 1976; 29:643–7.
139. Vas CJ. Sexual impotence and some autonomic disturbances in men with multiple sclerosis. Acta Neurol Scand 1969; 45:166–82.
140. Betts CD, Jones SJ, Fowler CG, Fowler CJ. Erectile dysfunction in multiple sclerosis. Associated neurologic deficits, and treatment of the condition. Brain 1994; 117:1303–10.
141. Ghezzi A, Malvestitti GM, Baldini S, et al. Erectile impotence in multiple sclerosis: a neurophysiological study. J Neurol 1995; 242:123–6.
142. Mattson D, Petrie M, Srivastava DK, McDermott M. Multiple sclerosis. Sexual dysfunction and its response to medications. Arch Neurol 1995; 52:862–8.
143. Valleroy ML, Kraft GH. Sexual dysfunction in multiple sclerosis. Arch Phys Med Rehabil 1984; 65:125–8.
144. Lundberg PO. Sexual dysfunction in patients with multiple sclerosis. Sex Disabil 1978; 1:218–22.
145. Kirkeby HJ, Poulsen EU, Derup J. Erectile dysfunction in multiple sclerosis. Neurology 1988; 38:1366–74.
146. Zorzon M, Zivandinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler 1999; 5:418–27.
147. Zorzon M, Zindinov R, Monti Bragadin L, et al. Sexual dysfunction in multiple sclerosis: a 2-year follow-up study. J Neurol Sci 2001; 187:1–5
148. Borello-France D, Leng W, O’Leary M, et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler 2004; 10:455–61.
149. Foley FW, Iverson J. Sexuality and multiple sclerosis. In Kalb RC, Scheinberg LC eds., Multiple Sclerosis and the Family. New York: Demos, 1992; 63–82.
150. Demirkiran M, Sarica Y, Uguz S, Yerdelen D, Aslan K. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Mult Scler 2006; 12:209–14.
151. Zorzon M, Zivadinov R, Locatelli L, et al. Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. Mult Scler 2003; 9:108–10
152. Zivadinov R, Zorzon M, Locatelli L, et al. Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study. J Neurol Sci 2003; 210:73–6.
153. Ernst R, Pittler MH. Yohimbine for erectile dysfunction: a new systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159:433–6.
154. Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998; 159:122–4.
155. Montague DK, Barada JH, Belker AM, et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156:2007–11.
156. Hellstrom WJ, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double blind, placebo controlled pivotal trial. Urology 2003; 61(Suppl 1):8–14.
157. Giuliano F, Donatucci C, Montorsi F, et al. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int 2005; 95:110–16.
158. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338:1397–404.
159. Skoumal R, Chen J, Kula K, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004; 46:362–9.
160. Fowler CG, Miller JR, Sharief MK, et al. A double blind randomized study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:700–5.
161. Derry F, Gardner BP, Glass C, et al. Sildenafil (Viagra): a double-blind, placebo-controlled, single-dose, two-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury [Abstract]. J Urol 1997; 157(Suppl):181.
162. Washington SL, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther 2010; 4:159–71.
163. Sonksen J, Biering-Sorensen F, Kristensen JK. Ejaculation induced by penile vibratory stimulation in men with spinal cord injuries. The importance of the vibratory amplitude. Paraplegia 1994; 32:651–60.
164. Heller L, Keren O, Aloni, R, Davidoff G. An open trial of vacuum penile tumescence constriction therapy for neurological impotence. Paraplegia 1992; 30:550–3.
165. Hirsch JH, Smith RL, Chancellor MB, et al. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994; 32:661–4.
166. Flynn RJ, Williams G. Long term follow-up of patients with erectile dysfunction commenced on self-injection with intracavernosal papaverine with or without phentolamine. Br J Urol 1996; 78:628–31.
167. Weiss JN, Badlani GH, Ravalli R, Brettschneider N. Reasons for high drop-out rate with self injection therapy for impotence. Int J Impot Res 1994; 6:171–4.
168. Massey EW, Pleet AB. Penile prosthesis for impotence in multiple sclerosis. Ann Neurol 1978; 5:451–4.
169. Goldstein I, Newman L, Baum N, et al. Safety and efficacy of Mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997; 157:833–9.
170. Randrup E, Wilson S, Mobley D, et al. Clinical experience with Mentor alpha 1 inflatable penile prosthesis. Urology 1993; 42:305–8.
171. Sexton WJ, Benedict JF, Jarow JP. Comparison of long term outcomes of penile prosthesis and intracavernosal injection therapy. J Urol 1998; 159:811–15.
172. Minderhoud JM, Leemhuis JG, Kremer J, et al. Sexual disturbances arising from multiple sclerosis. Acta Neurol Scand 1984; 70:299–306.
173. Hudson WW, Harrison DF, Crosscup PC. A short form scale to measure sexual discord in dyadic relationships. J Sex Res 1981; 17:157–74.
174. Tzortzis V, Skriapas K, Hadjigeorgiou G et al. Sexual dysfunction in newly diagnosed multiple sclerosis women. Mult Scler 2008; 14:561–3.
175. Langworthy OR. Disturbances in micturition associated with disseminated sclerosis. Nerv Ment Disord 1938; 88:760–70.
176. Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171:1189–93.
177. Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular response in women with spinal cord injury. Urology 2000; 55:812–15.